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Radiation therapy is a cornerstone in the therapeutic management of craniopharyngioma.
The close proximity to neighboring eloquent structures pose a particular challenge to
radiation therapy. Modern treatment technologies including fractionated 3-D conformal
radiotherapy, intensity modulated radiation therapy, and recently proton therapy are able to
precisely cover the target while preserving surrounding tissue,Tumor controls between 80
and in access of 90% can be achieved. Alternative treatments consisting of radiosurgery,
intracavitary application of isotopes, and brachytherapy also offer an acceptable tumor con-
trol and might be given in selected cases. More research is needed to establish the role
of each treatment modality.
Keywords: craniopharyngioma, radiotherapy, post-operative
INTRODUCTION
Surgery and radiotherapy are the cornerstones in therapeuticman-
agementof craniopharyngioma.Radical excision is associatedwith
a risk of mortality ormorbidity particularly as hypothalamic dam-
age, visual deterioration, and endocrine complication between 45
and 90% of cases. By contrast, recurrent disease after partial exci-
sion alone is observed between in 50 and 91% (Becker et al., 1999).
Today less radical surgery in combination with radiation ther-
apy are favored achieving a progression-free survival between 70
and 90% (Fahlbusch et al., 1999; Chiou et al., 2001; Tomita and
Bowman, 2005).
New technologies are currently under investigation to achieve
a better balance between tumor control and the risk for hazardous
effects for surrounding eloquent structures such as the pituitary
gland, hypothalamus, optic apparatus, and arteries at the base of
the skull.
ROLE OF RADIOTHERAPY/CONVENTIONAL TECHNOLOGIES
External fractionated radiotherapy is presently standard of care
to achieve an optimal progression-free survival after non-radical
excision (Wen et al., 1989; Hetelekidis et al., 1993; Merchant et al.,
2002; Stripp et al., 2004; Karavitaki et al., 2005; Lin et al., 2008).
An excellent long-term outcome of conventional radiotherapy
was found in many retrospective series reporting 10 and 20 years
progression-free survival up to 95 and 54% (Table 1).
MODERN TECHNOLOGIES IN RADIATION THERAPY
Advances in radiation therapy technologies have opened up
new approaches in the radio-oncological management of cranio-
pharyngioma. The selection of the adequate treatment technology
is of ongoing debate.
FRACTIONATED CONFORMAL RADIOTHERAPY/INTENSITY MODULATED
RADIATION THERAPY
With the use of modern imaging technologies and treatment plan-
ning systems a precise coverage of the tumor area can be achieved
by using stereotactic irradiation technologies. Stereotactic irradia-
tion can be given in a single dose as stereotactic radiosurgery or in
multiple doses as fractionated stereotactic radiotherapy. Themod-
ern systems permit an exact calculation of dose distributionwithin
the tumor and provide a steeper dose gradient to surrounding
normal tissue. If a cystic component is present, careful monitor-
ing during radiotherapy is necessary (Winkﬁeld et al., 2009). The
results are shown in Table 2.
PROTON THERAPY
The major advantage of proton therapy is the high degree of dose
conformity to the target. Beltran et al. (2011) retrospectively eval-
uated proton treatment plans with IMRT plan. He concluded that
compared with photon IMRT proton therapy has the potential to
signiﬁcantly reduce whole brain and body irradiation. Fitzek et al.
treated 15 patients with craniopharyngioma with a mix of photon
and protons. The tumor control rates at 5 and 10 years were 93 and
85%, respectively (Fitzek et al., 2006). Luu et al. (2006) treated 16
patients. Local control could be achieved in 14 of 15 patients (Luu
et al., 2006).
TIMING OF RADIATION THERAPY
Often immediate post-operative radiation therapy is favored in
order to obviate early tumor progression leading to a functional
deterioration caused by tumor growth or the necessity for repeat
surgery. Others favor a watch-and-wait strategy fearing the long-
term adverse effects of radiation therapy. The recent series of
Stripp et al. (2004), Tomita and Bowman (2005), and Moon et al.
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Table 1 | Post-operative radiotherapy in craniopharyngioma/conventional techniques (tumor control and survival).
Author Patients PFS (%) OS (%)
5 years 10 years 5 years 10 years
Carmel et al. (1982) 14 78 78 90 80
Habrand et al. (1999) 32 78 56 91 65
Flickinger et al. (1990) 21 95 95 89 89
Rajan et al. (1993) 173 – 83 – 77
Hetelekidis et al. (1993) 46 – 86 – 91
Mark et al. (1995) 25 96 – 96 96
Varlotto et al. (2002) 24 89.1 (10 years) 54 (20 years) 100 (10 years) 92.3 (20 years)
Pemberton et al. (2005) 87 77 (10 years) 66 (20 years) 86 (10 years) 76 (20 years)
PFS, progression-free survival; OS, overall survival.
Table 2 | Results after modern external fractionated radiotherapy techniques.
Author Patients Technique Dose PFS OS
Combs et al. (2007) 40 3-D conformal fractionated
stereotactic radiotherapy
Median 52.2Gy, range 50.4–
56Gy, 1.8–2Gy single dose
100% local control at 5 and
10 years
5/10 years 79/89%
Minniti et al. (2007) 36 3-D conformal fractionated
stereotactic radiotherapy
50Gy in 30–33 fractions 3–5 years 97/92% 3/5 years 100%
Kanesaka et al., 2011 (adults) 16 3-D conformal fractionated
stereotactic radiotherapy
30Gy in 6 fractions 3 year local control 82.4% 3year 94.1%
Hashizume et al. (2010) 10 FSRT Novalis IMRT 30–39Gy in 10–15 fractions
(median 33Gy)
Control rate 100% Not reported
Selch et al. (2002) 16 3-D conformal fractionated
stereotactic radiotherapy
55Gy fractionated 75% at 3 years 93% at 3 years
(2005) showednodifferences betweenprogression-free andoverall
survival between the different approaches (Table 3). However, in
the recent series of Lin et al. (2008) early radiation therapy yielded
a 100% local control rate at 10 years as compared with 32% when
radiation therapy was performed at relapse.
OTHER TECHNOLOGIES
RADIOSURGERY
Stereotactic radiosurgery is an alternative to fractionated treat-
ments in patients with craniopharyngioma harboring smaller
lesions. The reported results of radiosurgery, however, suggest
that tumor control is inferior to fractionated treatments and
might carry the risk for optic neuropathies unless only smaller
lesions are treated away from the optic apparatus (Tishler et al.,
1993). Minniti et al. (2009) reviewed eight published series
and found an average tumor control rate of 90% for solid
tumors, 88% for cystic tumors, and 60% for mixed tumors
(Table 4).
CYBERKNIFE
CyberKnife includes a compact linear accelerator mounted on a
robotic arm combined with the pair of diagnostic X-ray sources
permitting an online reproducibility of the incident beams and
a subsequent adjustment of the beam with a precision below
1mm. Lee et al. reported results obtained in 16 patients treated
Table 3 | Early versus delayed radiation therapy/impact on
progression-free and overall survival.
Author (year) Patients Early RT RT at relapse
Sung et al. (1981) 10 – 70.9%,
10 years OS
Regine et al. (1993) 58 78%,
20 years OS
25%,
20 years OS
Stripp et al. (2004) 40 83%,
10 years OS
86%,
10 years OS
Tomita and Bowman (2005) 30 71%,
5 years PFS
90%,
5 years PFS
Moon et al. (2005) 50 91.3%,
10 years PFS
91.2%,
10 years PFS
Lin et al. (2008) 31 100%,
10 years LC
32%,
10 years LC
RT, radiotherapy; OS, overall survival; PFS, progression-free survival; LC, local
tumor control.
for residual recurrent craniopharyngioma Tumor shrinkage was
achieved in 7 of these 11 patients and tumor control in another
3 patients. The overall tumor control was achieved in 91% of
patients without complications (Lee et al., 2008).
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INTERSTITIAL BRACHYTHERAPY
There is one report from Barlas et al. (2000) in two patients
in whom iodine125-seeds were implanted delivering a dose
of 67 and 60Gy to tumor periphery. Response was par-
tially observed in one and tumor completely resolved in the
other patient 24months after treatment. Radiation induced
Table 4 | Outcome after stereotactic single dose radiosurgery in craniopharyngioma (Gamma Knife).
Author Patients Dose PFS OS
Kobayashi et al. (2005) 98 Marginal dose 11Gy 61 and 54% at 5 and 10 years 94.1 and 91% at 5 and 10 years
Ulfarsson et al. (2002) 21 3–25Gy 34% n.a.
Amendola et al. (2003) 14 14Gy (11–20Gy) 86% All alive 6–86months
Chiou et al. (2001) 10 Median 16.4Gy 58% n.a.
Yu et al. (2000) 46 Marginal dose 8–18Gy 89.5% n.a.
Chung et al. (2000) 31 9.5–16Gy 87% n.a.
Mokry (1999) 23 Marginal dose 8–9.7Gy 74% n.a.
Prasad et al. (1995) 9 13Gy 62.5% n.a.
n.a., not analyzed.
Table 5 | Intracavitary instillation of radionuclides/impact on tumor control and visual function (modified according to Derrey et al., 2008).
Author Patients Isotope Complete
remission
Reduction No change expansion Tumor control Visual impairment
Voges et al. (1997) 62
78 C
Y 90 35/78 27/78 12/78 4/78 10 years OS 4/62
Rhe 186 Solid: 31%
P 32 Cystic: 64%
Blackburn et al. (1999) 6 Y 90 0 6 1 2 n.a. 1/5
9 C
Hasegawa et al. (2004) 41 P 32 7 24 5 5 10 years: 70% 3/40 (RT induced)
41 C Solid comp.: 32%
increase
Derrey et al. (2008) 39 Rhe 186 17 17 5 5 n.a. 3/39
44 C
C, cysts; Y 90, Yttrium 90; Rhe 186, Rhenium 186; P 32, Phosphorus 32; OS, overall survival.
Table 6 | Advantages and disadvantages of modern treatment technologies in radiotherapy of craniopharyngioma.
Technology Advantages Disadvantages
Conventional 2-D radiotherapy Reliable clinical data and long follow-up indicat-
ing high efﬁcacy of radiotherapy
Poor geometrical precision. No reliable protection of normal
surrounding tissue
Fractionated conformal radiation
therapy/IMRT
Excellent adjustment of treatment portals to
tumor site. In 3-D. Sparing of normal tissue
Rigid head ﬁxation (relocatable). Few patient numbers and not
yet long follow-up
Fractionated proton therapy Optimal coverage of tumor site. With maximal
sparing of surrounding tissue
Few patient numbers. Limited access, high costs
Radiosurgery Only one session. Excellent coverage of tumor.
Almost no dose to non-target tissue
Limited clinical settings. Tumor control inferior to fractionated
treatments? Low patient numbers. No long follow-up
Hypofractionated image guided
radiosurgery (CyberKnife)
Only few session. The biological advantages of
fractionation can be utilized. Excellent coverage
of tumor. Almost no dose to non-target tissue
Very few experiences. Role still unclear. No reliable data for
tumor control. No long-term follow-up. Only selected clinical
settings
Intracavitary colloid isotope application High tumor control rates for cystic components Only cystic tumors. Underdosage in solid components. Leak-
age possible. Detrimental effects on visual function reported
Interstitial irradiation (Iodine seeds) Excellent dose conformity. Optimal protection of
normal tissue
Very few clinical data
www.frontiersin.org December 2011 | Volume 2 | Article 100 | 3
Kortmann Radiation therapy of craniopharyngioma
toxicity or recurrence has not been reported 6 years after treat-
ment.
INTRACAVITARY APPLICATION OF ISOTOPES
Approximately 90% of craniopharyngioma display a cystic com-
ponent often leading to a space occupying clinically relevant effect.
There are different series reporting on the intracavitary appli-
cation of different isotopes such as Rhenium186, Yttrium90, or
Phosporus32. The nuclides emit β-rays with a therapeutic range
within only a few millimeters. Response rates and cyst controls
can be achieved in more than 80% of case. Tumors with a solid
component, however, are insufﬁciently controlled (Voges et al.,
1997; Hasegawa et al., 2004). Deterioration of visual function due
to ionizing irradiation of the nuclides can occur (Table 5).
CONCLUSION
Standard treatments today consist of fractionated external irra-
diation therapy. The recent developments in modern treatment
technologies permit an exact delineation of target and non-target
surrounding normal tissue (Merchant et al., 2006). Tumor con-
trol and overall survival might be improved as compared with
the excellent results obtained with conventional treatments at
shorter follow-up periods. Longer follow-up periods, however,
are warranted. Today the 5-year progression-free survival after
modern fractionated irradiation is in the range between 80 and
100%. Good results are achieved with a combined approach
(surgery+ radiation therapy) using standard fractionation. The
recently introduced proton therapy opens up the possibility for a
better sparing of normal surrounding tissue. Presently data are,
however, limited and the expected improvement of functional
outcome remains yet to be proven.
Post-operative radiation therapy is superior to surveillance after
non-radical resection in terms of progression-free survival. The
impact of different timing on functional outcome is still unknown.
The current prospective German study Craniopharyngioma 2007
is addressing this issue in a randomized prospective study.
Radiosurgery as an option for circumscribed small lesions away
from the optic apparatus is an attractive option because normal
surrounding tissue is excellently spared. Single dose radiotherapy
is, however, associated with an inferior tumor control according to
retrospective data.CyberKnife as a new technological development
utilizing image guided high precision stereotactic radiotherapy
is able to use the radiobiologically advantageous fractionation
concept. Interstitial treatments like the intracystic application of
radioactive colloids might be used in selected cases in which
only cystic tumors are present. It is, however, more a historical
experience and should not be favored in the area of modern treat-
ment technologies. Brachytherapy is of limited importance and
the experiences so far obtained are very scarce. Minimizing the
dose to non-target tissue will be the future step to reduce the risk
for late effects. Reproducible data in prospective settings including
neurocognitive function, quality of life, visual, and endocrinolog-
ical function are still missing and require further research and
evaluation. Table 6 gives an overview of the current technologies.
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